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Abstract 
Thirty-four  blood  samples  of  neonates  in
Dubai, UAE, with an MCV below 90 fL were
checked  by  high  performance  liquid  chro-
matography (HPLC) for hemoglobin variants
to  confirm  a  previous  study  carried  out  in
Western  Province  of  Saudi  Arabia  which
showed a very high predictive index of such
MCV for alpha (α-) thalassemia minor (ATM).
MCH  below  30  pg  was  an  additional  factor
which supported such a prediction. The Dubai
study confirmed the original finding with 100%
of such neonates showing Hb Barts band. A
control  group  of  26  neonates  with  an  MCV
between 90 and 95 fl showed Hb Barts in only
11 cases (42.3%). Of these, 6 (23.1%) were
preterm babies, expected to have higher MCV.
Five cases (19.2%) had an MCH below 30 pg,
though MCV was 90 or higher. Three of the
preterm babies also had MCH below 30. The
study confirmed the Saudi results in neonates.
It  seems  very  highly  probable  that  a  term
neonate with MCV below 90 and MCH below 30
has ATM.
Introduction
The presence of Hb Barts in blood at birth is
a  finding  in  α-thalassemia  trait,  intermedia
(HbH disease) and major (hydrops fetalis).
1,2
Diagnosis  of  α-thalassemia  major  is  not  a
problem  and  it  is  incompatible  with  life
3 as
most of the hemoglobin will be Barts. Neonates
with α-thalassemia intermedia have HbF, HbA
and Hb Barts, usually more than 15%.
4 This
condition is easy to diagnose later in life, even
if not investigated at birth, due to the presence
of HbH.
6
The problem lies with α-thalassemia trait,
single or double gene deletion types. Most of
these  cases  have  normal  HbA2  levels  if
checked after the age of six months,
6,7,8 though
red cell indices are thalassemic. This group,
which makes up the bulk of gene carriers, will
be difficult to confirm by Hb electrophoresis
(HBEP) or by HPLC in childhood and adult life.
If one can check HBEP or HPLC at birth then
presence of Hb Barts would put the diagnosis
on solid grounds. Hb Barts disappears a few
weeks after birth.
1
It is too expensive to perform HPLC or HBEP
for all neonates, even in areas where frequen-
cy of the α-thalassemia gene is high. So, if we
can predict, with cheap tests, the presence of
α-thalassemia then Hb separation can be per-
formed for the highly probable cases only. This
issue  was  addressed  by  work  carried  out  in
Thailand,
9 and in Jeddah, Saudi Arabia a few
years ago.
6 MCV below 90 and MCH below 30
were found to be of very high predictive value
in the Jeddah study.
There  was  a  need  to  repeat  the  study  in
another  setting,  where  thalassemics  are  of
variable ethnic groups, like in Dubai. α-tha-
lassemia is present in the UAE nationals and
residents  of  Iranian,  Arab,  Pakistani  and
Filipino origins in Dubai and it was expected
that neonates in such a population would make
a good sample for repetition of the study and
confirmation of the validity of using the MCV
and MCH as predictive parameters in individu-
als of various ethnic groups.
Materials and Methods
All  full  blood  counts  (FBC)  performed  for
neonates  were  checked.  Counts  were  per-
formed using a Coulter machine model LH7D1
(Beckman Coulter, Brea, Ca, USA). Thirty-four
consecutive neonates, with MCV below 90 fL
were  checked  by  HPLC,  using  Waters  2695
machine (Milford, Ma, USA), and short β-tha-
lassemia program, to look for Hb Barts band. 
Blood  films  of  all  babies  included  in  the
study were checked by the hematopathologist
for  red  cell  morphology.  FBCs  had  not  been
ordered for these babies because of any suspi-
cion of thalassemia. They were random and
judged to be necessary by the attending neona-
tologists for various reasons.
As a control group, 26 neonates, who had
MCV between 90 and 95 fL were also checked
by HPLC. Again, these were not selected and all
consecutive  cases  with  such  an  MCV  level
were included into the control group. It took
eight months to collect the entire test and con-
trol cases because only a minority of neonates
in Dubai have blood counts checked.
Results
All individuals in the test group had MCV
below 90 fL (mean 85.35, range 77-88.9). MCH
was  below  30  in  33/34  patients  (97%).  One
patient (3%) had an MCH of 31.1 pg. Mean
MCH was 27.82 and range 25.1-31.1. 
Hb  Barts  was  demonstrated  in  all  the  34
cases (100%). It ranged from a trace (less than
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Table 1. Results on cord blood of test group.
Hb Barts MCV MCH
<90 ≥90 <30 ≥30 Total cases
Positive 34  0  33 1 34
% 100 0 97 3
Negative 0 NA 00 0
00 0
Table 2. Results on cord blood of test group.
Hb Barts MCV MCH
<90 ≥90 <30 ≥30 Total cases
Positive NA 11 7 (3 preterm) 4 (3 preterm) 11
% 42.3 26.9 15.3 42.3
Negative NA 15 0 15 15
% 57.6 0 57.6 57.6[page 104] [Hematology Reviews 2009; 1:e20]
1%) to 10.6% (mean 4.65%). The 10.6% figure
was obtained in the baby with the lowest MCV
(77) and MCH (25.1) (Table 1), who had Hb
level of 12.5 and later proved to have Hb H dis-
ease. MCV in the control group ranged from
90.1 to 94.8 fL (mean 92.27) and MCH from
28.7  to  31.7  (mean  30.33).  Hb  Barts  was
demonstrated in 11 cases (42.3%). It ranged
from  2-6%  in  those  cases.  Fifteen  cases
(57.6%) were negative for Hb Barts. Analyzing
the 11 Barts-positive cases further showed that
7  of  them  had  MCH  below  30  and  6  were
preterm (3 of them had MCH below 30). Only
one baby (3.8%) out of the 26 controls and pos-
itive Barts had MCH above 30 and was full term
(Table 2). Blood films of all babies included in
the test group showed numerous target cells
and microcytosis, but no signs of active hemol-
ysis.
Discussion
After the work carried out in Jeddah, Saudi
Arabia,
6 where the population is basically local
with a low expatriate mix, as well as some vari-
ation in the origin of the local population itself,
it was thought useful to the medical literature
to repeat the study at another site to confirm
the remarkable results of the original study.
Medical  literature  does  mention  that  α-tha-
lassemia trait individuals are born with micro-
cytosis.
5,10,11 However, there is no clear demar-
cation of the level of MCV and MCH where one
can expect, with high confidence, to find α-
thalassemia.
3,5,11 The  work  carried  out  in
Thailand
9 took the MCV cut-off value of 95. In
our  experience,  in  both  works  performed  in
Jeddah and in Dubai a MCV cut-off value of 95
will give a lot of negative cases and make the
need  for  HPLC/HBEP  much  higher,  thus
increasing the cost while one of the objectives
of this scheme is to lower costs.
The advantage of using MCV and MCH lev-
els  is  that  these  values  are  easily  available
from a simple automated blood count (FBC). If
one can prove that there are limit levels for
these two parameters which carry a high prob-
ability of α-thalassemia trait and HbH disease,
then  there  will  be  a  small  proportion  of
patients for whom one needs to perform Hb
separation  procedure,  by  alkaline  electro-
phoresis or HPLC, to demonstrate Hb Barts,
and thus prove α-thalassemia presence. It is
confirmed from this study that if MCV is below
90  and/or  MCH  is  below  30  there  is  a  high
probability of over 95% that the case is α-tha-
lassemia trait. MCV may be above 90 if the
baby is born premature. In such cases one can
extend the MCV level to 95, whether or not
MCH is below 30 pg. It is noteworthy that Hb
Barts is not only a diagnostic finding for α-tha-
lassemia, but it tends to disappear a few weeks
after birth.
10 Trying to confirm β-thalassemia
trait at a later age, when suspicion is raised by
low red cell indices leading to erythrocytosis,
hematologists first resort to HBEP or HPLC,
looking for low HbA2. However, low HbA2 is not
a common finding in this condition.
6 Also, low
Hb A2 is found in other conditions, like βtha-
lassemia.  Iron  deficiency  anemia  may  also
lower HbA2 to below normal level.
12-14 Failing to
confirm the condition by this routine test, as in
the majority of cases, one can try molecular
studies on the α-polypeptide gene to look for
deletions or mutations known to lead to α-tha-
lassemia trait. These deletions and mutations
are so numerous
5,15,16 that, in practice, laborato-
ries  only  try  the  common  local  deletions  or
mutations, using the proper probes for them, if
these are known from previous studies. In a
mixed population the task will be difficult, as
one can imagine. The cost of these molecular
tests  is  certainly  higher  than  Hb  separation
studies.  In  parts  of  the  world  where  α-tha-
lassemia gene is of high frequency, the cost
will be enormous if one wants to diagnose all
carriers. It should be remembered that most
countries harboring a high frequency for the
gene are also poor in resources.
17 The simple
strategy we are recommending, proven by the
two studies in two different locations, is valid
and is recommended by the authors for WHO
and local public health schemes to establish
the  diagnosis  and  gene  frequency.  Further
studies are being considered to try to split pop-
ulations with one, two and three gene dele-
tions/mutations from levels of MCV and MCH
caused by them and the HPLC performed as a
result of obtaining the low MCV and MCH fig-
ures. The simple investigational scheme that
we  suggest  to  be  followed  for  the  α-tha-
lassemia screening of neonates is shown in
Figure 1.
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